ADIPOCYTOKINES IN RHEUMATOID ARTHRITIS: LATENT RELATIONASHIP BETWEEN INFLAMMATION AND CARDIOMETABOLIC COMORBIDITIES

Rheumatoid arthritis is a chronic autoimmune disease that affects the synovial membrane of the joints and leads to progressive articular damage, disability and reduced quality of life. Despite the emergence of more innovative therapeutic strategies that have improved the duration of remission, rheumatoid arthritis is associated with high levels of comorbidities, infections, malignancies and cardiovascular disease. It is known that some pathogenic proinflammatory mediators in rheumatoid arthritis, such as interleukin-1β (IL-1β) and tumour necrosis factor, may play a central role in the development of cardiovascular disease. Interestingly, various preclinical and clinical studies have shown that biologic agents, who are widely used in the therapy of patients with rheumatoid arthritis, may be effective in the therapy of cardiovascular diseases as well. For this purpose we have studied adipocytokines. Adipocytokines are pleiotropic molecules that are mainly released by white adipose tissue and immune cells. Adipocytokines modulate the function of different tissues and cells, and, in addition to energy homeostasis and metabolism, enhance inflammation, immune response and tissue damage. Adipocytokines may contribute to the proinflammatory conditions in patients with rheumatoid arthritis and the development of bone damage. In addition, they may be associated with the development of cardiovascular disease. In this study, we considered the already known evidence about adipocytokines in the pathogenesis of rheumatoid arthritis, because they are also actively involved in the pathogenesis of cardiovascular disease and are possible biomarkers of prognosis and treatment outcomes, because of their potential, as a possible new therapeutic target.

Download Full-text

Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities

Journal of Immunology Research ◽

10.1155/2018/8410182 ◽

2018 ◽

Vol 2018 ◽

pp. 1-10 ◽

Cited By ~ 11

Author(s):

Piero Ruscitti ◽

Paola Di Benedetto ◽

Onorina Berardicurti ◽

Vasiliki Liakouli ◽

Francesco Carubbi ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Energy Homeostasis ◽

Interleukin 1 ◽

High Rate ◽

Proinflammatory Mediators ◽

Bone Damage ◽

Articular Damage ◽

Preclinical And Clinical Studies ◽

Chronic Autoimmune Disease

Rheumatoid arthritis is a chronic autoimmune disease affecting typically synovial joints and leading to progressive articular damage, disability, and reduced quality of life. Despite better recent therapeutic strategies improving long-term outcomes, RA is associated with a high rate of comorbidities, infections, malignancies, and cardiovascular disease (CVD). Remarkably, some well-known pathogenic proinflammatory mediators in RA, such as interleukin-1β (IL-1β) and tumor necrosis factor (TNF), may play a pivotal role in the development of CVD. Interestingly, different preclinical and clinical studies have suggested that biologic agents commonly used to treat RA patients may be effective in improving CVD. In this context, the contribution of adipocytokines has been suggested. Adipocytokines are pleiotropic molecules, mainly released by white adipose tissue and immune cells. Adipocytokines modulate the function of different tissues and cells, and in addition to energy homeostasis and metabolism, amplify inflammation, immune response, and tissue damage. Adipocytokines may contribute to the proinflammatory state in RA patients and development of bone damage. Furthermore, they could be associated with the occurrence of CVD. In this study, we reviewed available evidence about adipocytokines in RA, because of their involvement in disease activity, associated CVD, and possible biomarkers of prognosis and treatment outcome and because of their potential as a possible new therapeutic target.

Download Full-text

ETIOPATHOGENESIS AND MANAGEMENT OF WAJAAL-MAFASIL (RHEUMATOID ARTHRITIS): AN EVIDENCE-BASED COMPREHENSIVE REVIEW

International Journal of Research in Ayurveda and Pharmacy ◽

10.7897/2277-4343.1206180 ◽

2022 ◽

Vol 12 (6) ◽

pp. 96-103

Author(s):

Ansari Umme Ammara Maqbool Ahmad ◽

Qamar Uddin ◽

Bhoraniya Abdullah Ismail ◽

Juveria Jabeen

Keyword(s):

Rheumatoid Arthritis ◽

Indian Subcontinent ◽

Scientific Evidence ◽

Review Article ◽

Alternative Source ◽

Unani Medicine ◽

Preclinical And Clinical Studies ◽

Chronic Autoimmune Disease ◽

Inflammatory Polyarthritis

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by symmetrical inflammatory polyarthritis involving small joints of the hand and feet. It has a global prevalence of 0.8 to 1% in Europe and the Indian subcontinent. Rheumatoid arthritis (Waja‘al-Maf?sil) had been broadly described and managed by the Unani scholars since antiquity. Many pharmacological and non-pharmacological treatment methods are available in the classical Unani literature. The treatment differs for different varieties of morbid humour involved in disease pathogenesis. Treatment aims to reduce morbidity and prevent disability, subsequently improving the quality of life. This review article mainly highlights the management of rheumatoid arthritis mentioned in classical Unani literature and supportive scientific evidence of various preclinical and clinical studies suggesting the potential of Unani medicine. This review article aims to explore the concept of rheumatoid arthritis in the Unani system of medicine to provide a better understanding of disease and its management through the holistic policy of Unani medicine. This review may conclude that Unani treatment can form an alternative source to manage RA.

Download Full-text

Perspectives of Quality of Life improvement in patients with rheumatoid arthritis with administration of fully human anti-tumor necrosis factor alpha monoclonal antibodies

Rheumatology Science and Practice ◽

10.14412/1995-4484-2008-659 ◽

2008 ◽

Vol 0 (3) ◽

pp. 49

Author(s):

V N. Amirdjanova

Keyword(s):

Quality Of Life ◽

Rheumatoid Arthritis ◽

Monoclonal Antibodies ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Necrosis Factor Alpha ◽

Life Improvement ◽

Factor Alpha ◽

Necrosis Factor

Download Full-text

Proportion and Factors that Associate with Incidence of Hepatotoxicity in Rheumatoid Arthritis Patients Treated with Methotrexate in RSCM Year 2013−2015

Indonesian Journal of Rheumatology ◽

10.37275/ijr.v10i1.92 ◽

2018 ◽

Vol 10 (1) ◽

Author(s):

Rahma Anindya Prathitasari ◽

Harry Isbagio

Keyword(s):

Quality Of Life ◽

Rheumatoid Arthritis ◽

Autoimmune Disease ◽

Aspartate Aminotransferase ◽

Alanine Aminotransferase ◽

Side Effect ◽

Normal Limit ◽

Keywords Rheumatoid Arthritis ◽

Chronic Autoimmune Disease

Background Rheumatoid arhtirtis (RA) is a chronic autoimmune disease that mainly attacks joints. It may causes joint deformities which leads to lower quality of life of RA patients. RA is treated with metothrexate (MTX) which inhibiting disease progression. MTX is known for its hepatotoxicity side effect, which is described by an elevation of aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) beyond the upper normal limit. Factors that may enhance hepatotoxicity are gender, age, cummulative dose of MTX, and duration therapy of MTX. Prevalence of hepatotoxicity caused by MTX therapy in RA patients in Indonesia is still unknown. The objective of this research is to know the proportion of hepatotoxicity and its associations with the factors that may enhance hepatotoxicity caused by MTX therapy in RA patients in RSCM.Method Data about gender, age, cummulative dose and duration therapy of MTX are obtained from 115 RA patients' medical records.Result Proportion of hepatotoxicity in RA patients treated with MTX in RSCM is 42.60%. Gender, age, cummulative dose and duration therapy of MTX do not significantly enhance hepatotoxicity (p>0.05).Conclusion In conclusion gender, age, cummulative dose and duration therapy of MTX do not have association with hepatotoxicity in RA patients treated with MTX. Keywords: Rheumatoid Arthritis, Methotrexate, Hepatotoxicity

Download Full-text

Anti-Arthritis Effect through the Anti-Inflammatory Effect of Sargassum muticum Extract in Collagen-Induced Arthritic (CIA) Mice

Molecules ◽

10.3390/molecules24020276 ◽

2019 ◽

Vol 24 (2) ◽

pp. 276 ◽

Cited By ~ 5

Author(s):

Hyelin Jeon ◽

Weon-Jong Yoon ◽

Young-Min Ham ◽

Seon-A Yoon ◽

Se Kang

Keyword(s):

Inflammatory Response ◽

Immunohistochemical Analysis ◽

Cartilage Destruction ◽

Sargassum Muticum ◽

Mice Model ◽

Articular Damage ◽

Tnf Α ◽

Anti Inflammatory ◽

Chronic Autoimmune Disease ◽

Necrosis Factor

(1) Background: Rheumatoid arthritis is a chronic autoimmune disease that causes progressive articular damage and functional loss. It is characterized by synovial inflammation that leads to progressive cartilage destruction. For this reason, research on functional foods that reduce the inflammatory response are under progress. (2) Methods: We focused on the anti-inflammatory effects of Sargassum muticum, and confirmed the effect of the extract on the collagen-induced arthritis (CIA) DBA/1J mice model. (3) Results: The extract was given at concentrations of 50, 100, and 200 mg/kg, and the arthritis score and edema volume of the experimental group were significantly different from the CIA group. The level of interleukin (IL)-6, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ were determined in serum and lymphocytes. The expression of these cytokines in the serum remarkably decreased from S. muticum extract (SME)100 mg/kg, and decreased from SME 200 mg/kg in lymphocytes. Also, immunohistochemical analysis of IL-6 and TNF-α in the joints revealed that the inflammatory response was noticeably lower when treated with S. muticum extract. (4) Conclusions: This study provides results of the experiment of S. muticum extract treatment in a mouse model. The treatment was found to contribute to the alleviation of edema and symptoms by reducing the expression of inflammatory cytokines. It was concluded that it may be a useful substance to help in the mitigation of arthritis symptoms.

Download Full-text